Oxacillin plus ertapenem rapidly clears persistent left ventricular assist device‐related methicillin‐susceptible Staphylococcus aureus bacteremia. Issue 7 (7th April 2022)

• Record Type: Journal Article
• Authors: Wilsey, H. Andrew; Pisani, Barbara; O'Neill, Thomas J.
• Is Part Of: Journal of cardiac surgery. Volume 37:Issue 7(2022)
• Page Start: 2127
• Page End: 2130
• Publication Date: 2022-04-07
• Subjects: bacteremia -- combination therapy -- ertapenem -- LVAD infection -- oxacillin -- Staphylococcus aureus; Heart -- Surgery -- Periodicals; 617.412005
• DOI: 10.1111/jocs.16491
• Languages: English
• ISSNs: 0886-0440

Abstract

Abstract: There is an increasing use of left ventricular assist devices (LVADs) as bridge to transplantation or permanent destination therapy in the heart failure patient population. Infection remains a common complication in LVADs, with Gram‐positive skin flora as predominant pathogens implicated, including Staphylococcus aureus . While there is emerging evidence for synergistic antibiotic combinations with methicillin resistant S. aureus, there remains a significant gap in the literature for persistent methicillin susceptible S. aureus bacteremia. In this article, we describe the first successful treatment of persistent LVAD‐related bacteremia with salvage oxacillin plus ertapenem. The salvage therapy described here must be balanced by the risks for toxicity, impact on resistance, microbiota disruption, drug shortages, and patient costs. This combination warrants further evaluation in the clinical setting to better establish its role in our expanding patient population.